(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.38%) $78.41
(0.47%) $2.15
(0.44%) $2 318.70
(1.64%) $27.13
(-0.40%) $961.40
(0.01%) $0.929
(-0.05%) $10.87
(-0.01%) $0.797
(0.00%) $91.45
Live Chart Being Loaded With Signals
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally...
Stats | |
---|---|
今日成交量 | 61 225.00 |
平均成交量 | 17 264.00 |
市值 | 14.23M |
EPS | CHF0 ( 2024-04-13 ) |
Last Dividend | CHF0 ( N/A ) |
Next Dividend | CHF0 ( N/A ) |
P/E | -0.160 |
ATR14 | CHF0.00800 (0.69%) |
RELIEF THERAPEUTICS 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
RELIEF THERAPEUTICS 财务报表
Annual | 2023 |
营收: | CHF6.03M |
毛利润: | CHF-10.86M (-179.99 %) |
EPS: | CHF-8.35 |
FY | 2023 |
营收: | CHF6.03M |
毛利润: | CHF-10.86M (-179.99 %) |
EPS: | CHF-8.35 |
FY | 2022 |
营收: | CHF6.08M |
毛利润: | CHF-12.03M (-197.78 %) |
EPS: | CHF-4.80 |
FY | 2021 |
营收: | CHF3.32M |
毛利润: | CHF-16.45M (-495.42 %) |
EPS: | CHF-0.0144 |
Financial Reports:
No articles found.
RELIEF THERAPEUTICS
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。